Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities

Hopes RIse As Diverse Contenders Enter Late-Stage Trials

Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.

tunnel — Will There Be Light After A Long Tunnel? • Source: Shutterstock

With a few South Korean pharma firms now entering late-stage clinical trials for their Alzheimer's disease drug candidates, and many others actively pursuing development, hopes are brewing that the country will emerge as a challenger in the difficult space despite the high failure rates and ongoing controversies over Biogen, Inc.'s Aduhelm (aducanumab).

Smaller bioventures, rather than large pharma companies, appear to be more active at present, with several major firms including